IN
Innoviva, Inc.
INVA · NASDAQ
$20.55 -3.11% (-$0.66)
1M -3.75%
Market Cap $1.55B
P/E Ratio 4.35x
Div. Yield -
ROE 30.03%
Bulios Fair Price
$29.04
41.3% upside
Current Price
$20.55
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INVA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
95 /100
Cheap P/E 4.35x
PEG 0.01x
EV/EBITDA 1.52x
Growth
57 /100
Stable EPS growth 11.67%
Book val. growth 27.51%
Rev. growth 8.66%
Profitability
100 /100
Strong Gross margin 73.09%
FCF margin 42.47%
Net margin 80.56%
Quality
67 /100
Excellent ROIC 8.36%
Asset turnover 0.26x
ROE 30.03%
Debt
100 /100
Low Debt/Equity 0.22x
Net debt/EBITDA -0.37x
Current ratio 16.01x
Stability
47 /100
Moderate Beta 0.33x
Profitable years 6
Rev. volatility 13.55%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INVA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Pavel Raifeld
Employees
159
Headquarters
Burlingame
Upcoming events
04 NOV
Earnings
Upcoming earnings report